Company profile
ATOSSA THERAPEUTICS, INC.
NASDAQ:ATOSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ENDOXIFEN | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05607004 | phase2 | active_not_recruiting | 2023-02-14 | 2026-11-01 | Atossa Therapeutics, Inc. | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
| NCT07869732 | phase2 | not_yet_recruiting | 2027-03-01 | 2028-06-01 | Atossa Therapeutics, Inc. | (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty |
| NCT02540330 | phase2 | terminated | 2016-03-01 | 2020-08-13 | Atossa Therapeutics, Inc. | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant |
| NCT04519788 | phase1 | completed | 2020-08-07 | 2020-12-08 | Atossa Therapeutics, Inc. | AT-301 Nasal Spray in Healthy Adults |
| NCT05068388 | phase2 | completed | 2021-12-21 | 2024-06-14 | Atossa Therapeutics, Inc. | Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density |
FDA applications (0)
No records yet.